This report provides an updated classification of inborn errors of immunity (IEIs) involving 508 different genes and 17 phenocopies. Of these, we report 67 novel monogenic defects and 2 phenocopies due to neutralizing anti-cytokine autoantibodies or somatic mutations, which either have been discovered since the previous update (published June 2022) or were reported earlier but have been recently confirmed and/or expanded. The new additions were made after rigorous review of new genetic descriptions of IEIs by the International Union of Immunological Societies (IUIS) Expert Committee using criteria established to define IEI. Although similar pathogenic variants in one gene, in terms of both classes of mutation (missense, nonsense, etc.) and impact on protein function, can result in a spectrum of phenotypic manifestations, they are herein classified according to the most consistently reported phenotype. In addition, because different variants in a single gene can result in recognizable diseases due to gain or loss of function, such cases are classified according to their clinical manifestations as a distinct entry in the same or a different table depending on the associated phenotype. This report will serve as a valuable resource for clinical immunologists and geneticists involved in the molecular diagnosis of individuals with heritable and acquired immunological disorders. Moreover, we expect this report to also serve as a valuable resource for all disciplines of medicine, since patients with IEIs may be first seen by rheumatologists, hematologists, allergists, dermatologists, neurologists, gastroenterologists, and pulmonologists, depending upon their spectrum of presenting clinical features. Finally, expanding the known monogenic and related causes of human immune diseases requires dissection of underlying cellular and molecular mechanisms, which reveals fundamental requirements for specific genes, pathways, processes, and even cell types. Such knowledge may not only contribute to improved patient diagnosis and management but also pave the way to the development and implementation of therapies that target the cause—rather than the symptoms—of these conditions.

Inborn errors of immunity (IEIs) are, by definition, caused by damaging germline variants in single genes. IEIs present clinically as increased susceptibility to infections, autoimmunity, autoinflammation, allergy, bone marrow failure, and/or malignancy. Although individual IEIs are rare, collectively IEIs are not, and they represent a significant health burden (1). Indeed, a recent study reported that the incidence of IEIs in the USA was 6 per 10,000 people (2). Genetic variants underlie IEI by altering the encoded gene product, such as abolition (null) or reduction (hypomorphic) of protein expression, titration of the intrinsic function of the protein (gain of function [GOF] or loss of function [LOF]), or acquiring novel functions (neomorphic) (3, 4). Mechanisms of disease in IEIs depend on the nature of the variant and mode of inheritance. Thus, monoallelic variants can cause disease by haploinsufficiency, negative dominance, or GOF. In contrast, biallelic genetic lesions (homozygous, compound heterozygous) cause autosomal recessive (AR) traits by loss of expression, LOF, GOF, or neomorphic function of the encoded protein. X-linked recessive traits arise from LOF or GOF variants on the X chromosome, either in hemizygosity in males or in a homozygous state in females.

The careful genetic dissection and functional study of individual IEIs has aided in confirming or contrasting the knowledge obtained from mouse models or has offered novel insights on protein function within different immune pathways and specific immune cells (5, 6). Thus, by linking defined monogenic defects with clinical phenotypes of immune dysregulation, IEIs represent elegant models of the human immune system and have thus been referred to as “experiments of nature” (7). IEIs have also revealed mechanisms of disease pathogenesis and enabled the implementation of gene- or pathway-specific therapies for the treatment of rare and common conditions and established fundamental aspects of human immunology (8, 9, 10). Thus, the study of IEIs has driven profound advances in molecular medicine and human biology.

Since 1970, an international expert committee comprising pediatric and adult clinical immunologists, clinician/scientists, and researchers in basic immunology—initially under the auspices of the World Health Organization and currently the International Union of Immunological Societies (IUIS)—has provided the clinical and research communities with an update of genetic causes of immune deficiency and dysregulation (https://iuis.org/committees/iei/).

IEIs are currently categorized into 10 tables, with subtables segregating groups of disorders into overlapping phenotypes. These tables describe combined immunodeficiencies (Table 1; 3 subtables); combined immunodeficiencies with syndromic features (Table 2; 9 subtables); predominantly antibody deficiencies (Table 3; 3 subtables); diseases of immune dysregulation (Table 4; 7 subtables); congenital defects of phagocytes (Table 5; 4 subtables); defects in intrinsic and innate immunity (Table 6; 9 subtables); autoinflammatory diseases (Table 7; 3 subtables); complement deficiencies (Table 8); bone marrow failure (Table 9); and phenocopies of IEIs (Table 10) (Fig. 1, A and B) (4).

The committee strives to publish an updated report every 2 years to consolidate advances and catalog current IEIs (4). A large array of genetic variants related to IEI has been reported recently. Rather than including every candidate gene published in the peer-reviewed scientific literature, the committee applies stringent criteria to classify gene defects as novel causes of IEIs (11). These criteria include the following:

  • (1)

    The candidate genotype is monogenic and is not found in individuals without the clinical phenotype (recognizing that some conditions have incomplete penetrance).

  • (2)

    Experimental studies establish that the genetic variant impairs, destroys, or alters expression or function of the gene product.

  • (3)

    The causal relationship between the candidate genotype and the clinical phenotype must be confirmed via a relevant cellular phenotype, including—where possible—rescue of a functional defect (11).

These criteria can be met by the publication of multiple cases from unrelated families, including detailed immunological data; or publication of very few—even single—cases with compelling mechanistic data, often revealed from complementary studies in animal or cell culture models. With the number of genes and conditions growing, the committee also considers it essential that the immunological phenotype is described in-depth beyond the clinical phenotype. We also considered whether sufficient justification was provided to exclude alternative candidate gene variants identified in single cases, the depth of the clinical descriptions of the affected individuals, and the level of immune and functional characterization. It is important to consider that for specific diseases, even though at this point they fulfill the criteria to be included in these tables, building evidence may argue against disease causality. Indeed, stringent criteria are being developed to remove certain genes or inheritance modes from this list in the future.

This 2024 IUIS IEI update is intended as a follow-up resource for clinicians and researchers, and it can guide the design of panels used for targeted gene sequencing to facilitate clinical genetic diagnoses of IEI. Here, we summarize data on the genetic cause of 67 novel IEIs, and 2 phenocopies of IEI due to either autoantibodies (n = 1) or somatic mutations (n = 1), that have been assessed since the previous update (12). This increases the number of genes associated with IEI to 508, causing 559 conditions (Fig. 1 A). This includes four chromosomal deletion syndromes (22q11.2 deletion syndrome [DS], chromosome 11q DS, 10p13-p14DS [Table 2, subtables 3 and 9], and 14q 32 DS [Table 2, subtable 4]), as well as KRAS, NRAS, and UBA1, for which disease is only described due to somatic variants (Table 10). Given the rapid pace of discovery, the current update will likely be outdated by the time of its publication.

One gene, several phenotypes

For this update, IEIs are classified according to the predominant clinical presentation. However, patients with pathogenic mutations in specific IEI-associated genes may have clinical presentations that differ from the predominant clinical presentation under which they have been classified in this document, thereby expanding the phenotypic spectrum of disease. In this regard, some previously reported genes and IEIs have been reclassified into a different table after panel discussion. Nevertheless, it is important to stress that the disease-causing effect of a genetic variant cannot be excluded solely because the description of the classic phenotype in this table does not fit with the clinical presentation of a given patient. Indeed, the presenting phenotype of many IEIs is gradually expanding and this must be taken into careful consideration. One example of this is mutations in the WD40 domain of COPA causing COPA syndrome with arthritis and alveolar hemorrhages as the main clinical manifestations (13). However, patients with mutations in the C-terminal domain can have a wide spectrum of clinical manifestations including autoimmunity and neuroinflammation (14). It is therefore challenging to exclude pathogenicity of a novel variant, even if the phenotype is not typical for the described gene defect as the mechanism of disease and phenotype may differ based on the location of the variant. Furthermore, several IEIs may have incomplete penetrance (i.e., JAK1 GOF, PLCG2 LOF, NLRC4 GOF, PTPN2, among others) increasing complexity of genomic analysis, given that diseased individuals may have healthy family members carrying the same variant. Different factors may contribute to incomplete penetrance, and these are still not fully understood. Monoallelic expression has recently been identified as an important contributor to incomplete penetrance and should be taken into consideration (15).

Redefining or broadening of the clinical phenotype can also occur simply by the description of additional patients. Examples include AR MYD88 and IRAK4 deficiencies, which have been associated with susceptibility to invasive pyogenic bacterial infections, but recently have been found to cause severe viral infections (including coronaviruses and influenza) in some affected individuals (16). Alternatively, gene dose can impact disease phenotype and severity, in diseases that are classically described as AR disorders. An example of this phenomenon is mutations in RAG1, in which biallelic LOF mutations classically cause SCID, but patients with biallelic hypomorphic mutations can present later in life with combined immunodeficiency or milder immune dysregulation depending on residual RAG activity (17, 18). These findings challenge the assumption that IEIs are inevitably ultrarare and severe diseases affecting primarily children. Rather, they may include more common disorders that can present across the lifespan or even exclusively after exposure to specific microorganisms (19). Because of the expanding phenotypes, we have updated tables with less restrictive titles, and we foresee that current classifications will need to be reconsidered as the spectrum of disease associated with individual genes can be diverse and as several signaling pathways often illicit disease in a concerted action.

Clinically and phenotypically distinct IEI can arise due to variants in the same gene that have divergent molecular mechanisms such as LOF, GOF, and neomorphic or multimorphic function. Examples of this are mutations in IRF4, with one new entry causing AD combined immunodeficiency (Table 1, subtable 3) due to a mutation resulting in a neomorphic function (20) and two entries in Table 6, subtable 9, causing either Whipple disease by haploinsufficiency or antibody deficiency by another AD neomorphic variant (20, 21, 22). Similarly, CARD11 has three entries in three different tables as different inheritance patterns and pathogenic mechanisms lead to distinct phenotypes. OTULIN also appears three times—all in Table 7, subtable 3—due to distinct mechanisms of disease (heterozygous dominant negative or haploinsufficiency; AR LOF) that still manifest with similar clinical phenotypes. STAT1 and STAT3 have different entries in different tables because mutations in these genes lead to dramatically different phenotypes by GOF or LOF. This also emphasizes the crucial need to undertake in-depth in vitro functional validation of any novel variant considered to be potentially pathogenic. As a result, in this current update, >40 genes have more than one entry either in the same table or in different tables. Considering this complexity, counting IEI has become increasingly difficult. To improve clarity, for this version, we decided to count the number of monogenic IEI conditions and, separately, the number of genes causative of disease. If mutations in a gene cause disease with a similar phenotype yet follow an AR/AD inheritance pattern, they were counted as one condition (e.g., AD or AR LOF variants in AICDA, STAT1, or AIRE). If the diseases caused by a pathogenic variant in a single gene following AR/AD inheritance present as distinct phenotypes, they are counted as two different conditions (e.g., AD or AR variants in CARD11, PIK3R1; GOF or LOF variants in STAT1 or STAT3). With evolving genetic and pathophysiological insight, the number of IEI may change in the future as some conditions might be considered a spectrum of one disease rather than truly different conditions. As a result, comparing the numbers with previous versions would not be accurate as the criteria for counting are continuously evolving.

The discovery of novel IEI continues to demonstrate that distinct variants or zygosity in the same gene can cause disparate clinical conditions. In the current update, UNC93B1 is an example. Whereas AR UNC93B1 LOF was identified previously as an IEI underlying herpes simplex encephalitis, recent findings link heterozygous UNC93B1 GOF variants to childhood-onset systemic lupus erythematosus (SLE) (23, 24); furthermore, mouse models have revealed a gene dosage effect of Unc93b1 GOF variants (25).

Novel IEIs

Since the last update in 2022 (12), novel gene defects have been found for most categories of IEI, including novel causes of:

  • Combined immunodeficiencies: IRF4 (AD neomorphic); NFATC1, PRIM1, POLD3, NUDCD3 (AR LOF); and FOXI3, PSMB10 (AD LOF) (20, 26, 27, 28, 29, 30, 31, 32) (Table 1, subtable 1);

  • Combined immunodeficiencies with syndromic features: IKZF2 (dominant negative); GINS4, SLC19A1, SGPL1, FLT3L, ITPR3, RECQL4 (AR LOF); PTCRA (AR LOF/hypomorphic); SMAD3 (AD); and STAT6 (AD GOF) (33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47) (Table 2, subtable 1);

  • B-cell deficiencies, agammaglobulinemia or hypogammaglobulinemia PAX5, PI4KA, KARS1 (48, 49, 50) (all AR LOF; Table 3, subtable 1);

  • Immune dysregulation: CD274 (PDL1), CBLB, SH2B3, ARPC5, NFATC2, DOCK11, RHBDF2, LACC1, NBEAL2, IL27RA, TNFSF9, DPP9, GIMAP6 (AR LOF); ERN1, PTPN2 (AD LOF); TRAF3 (AD haploinsufficiency); and TLR7, UNC93B1, PLCG1 (AD GOF) (23, 25, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72) (Table 4, subtable 1);

  • Neutropenia: DBF4, SRP19, SRPRA, CCR2 (73, 74, 75) (all AR LOF; Table 5, subtable 1);

  • Innate immune defects resulting in susceptibility to mycobacterial/bacterial (IRF1, MCTS1 [76, 77]) and viral (OAS1, OAS2, RNASEL, RIPK3, MD2, TLR4, GTF3A, IKBKE [78, 79, 80, 81, 82, 83]) infections (all AR LOF; Table 6, subtable 1);

  • Autoimmune/autoinflammatory disorders: PMVK, SHARPIN, LSM11, RNU71 (AR LOF);ALPK1, ARF1 (AD LOF);OTULIN (two entries, both AD); RELA (DN); and STAT4, LYN (AD GOF) (84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94). Heterozygous LOF variants in RELA have been previously described as causing mucocutaneous inflammation and fever but are included as a new disease in this update as novel descriptions of DN mutations are associated with an inflammatory phenotype driven by TLR7 upregulation and enhanced secretion of interferons (Table 7, subtable 1). Specific c.61G>C variants in NLRP3 are noted to cause keratitis fugax hereditaria (95, 96);

  • Bone marrow failure: DCLRE1B, DUT, RAD50 (97, 98, 99) (all AR LOF; Table 9, subtable 1);

  • Phenocopies of IEI: a somatic variant in JAK1 (AD GOF) (100) and autoantibodies against IL-27 (68) (Table 10, subtable 1).

New entries for each table are shown in bold in the Tables below.

Phenocopies of known IEIs confirm critical pathways for immune function

Some of these novel genetic findings link common clinical phenotypes that converge on a shared pathway. Examples in this update include the following:

  • PRIM1 encodes the catalytic subunit of the DNA primase as part of the DNA polymerase complex that includes POLA1 and POLD, mutations in which are associated with immunodeficiency and distinct syndromic features. Biallelic mutations in PRIM1 cause primordial dwarfism characterized by growth retardation, microcephaly, and developmental delay with B-cell deficiency, but unlike patients with defects in POLA1 and POLD have normal T-cell numbers with conserved proliferation (28).

  • GINS4 is a component of the DNA replication machinery of mammalian cells and forms part of multimeric/multiprotein “replisome” complexes (101). Biallelic mutations in GINS4 result in a clinical phenocopy of AR deficiency of MCM10, MCM4, or GINS1 genes (34, 102, 103) that encode key proteins involved in DNA replication (101).

  • Description of AR PMVK deficiency, which functions upstream of MVK, confirms the pathogenic effect of disturbed mevalonate metabolism, resulting in an autoinflammatory disease (87).

  • Recently described NUDCD3 deficiency builds on the crucial role of RAG-mediated recombination, with pathologic sequestration of RAG1 in the nucleoli in the absence of NUDCD3 (31).

IEIs define specific roles for known genes and reveal immune-specific functions of novel genes

The description of patients with IEIs and study of the pathogenic mechanism of IEIs can demonstrate nonredundant and redundant functions of a specific gene in human immunity, and reveal similarities and differences between functions of specific genes in mouse and human immunology. Examples are as follows:

  • NUDCD3 was mostly known as a chaperone protein, with only hints at a potential role in the immune system through interactome studies. We have now learned that it plays a crucial role in optimal localization of RAG1 necessary for recombination of T-cell and B-cell antigen receptors (31).

  • Studies in mice have established that FLT3L functions as a hematopoietic factor essential for the development of natural killer (NK) cells, B cells, and dendritic cells (DCs) (104, 105). The identification of three patients with AR FLT3L deficiency confirmed that FLT3L is also required for B-cell and DC development in humans. However, unlike mice, human FLT3L is required for the development of monocytes but not NK cells (41).

  • Study of patients with PTCRA variants taught us that, unexpectedly, the majority have remained healthy at ages 2–65 years, whereas others had severe infection, lymphoproliferation, or autoimmunity, developing during adolescence or adulthood. Further investigation of individuals with hypomorphic PTCRA variants showed that memory αβ T cells can develop in the absence of human pre-TCRα and that human pre-TCRα is largely redundant for αβ T-cell development. However, complete or partial deficiency can lead to late-onset clinical manifestations, with incomplete penetrance (40).

  • PSMB10 was previously described as an AR disease gene for the autoinflammatory disorders PRAAS5, but specific, sporadic heterozygous variants in the same gene are clearly associated rather with a SCID/Omenn phenotype. The distinct behavior of such variants is not yet understood in terms of pathomechanism (32).

Recently identified IEIs have also revealed critical roles for genes in new disease contexts. For instance, our previous update highlighted the role of the type I IFN pathway in host defense against SARS-CoV-2 with the identification of germline defects in this pathway or autoantibodies against type I IFNs associated with severe COVID-19 (12). Subsequent studies related to the COVID-19 pandemic have included children presenting with multisystemic inflammatory syndrome (MIS-C) after SARS-CoV-2 infection and uncovered AR deficiencies of OAS1, OAS2, or RNASEL in around 1% of patients with this severe inflammatory complication. These gene products function in the same signaling pathway to suppress inflammation after double-stranded RNA detection. Thus, AR OAS1, OAS2, and RNASEL deficiencies result in uncontrolled inflammatory cytokine production that can underlie inflammation in some patients (78).

The role of autoantibodies in susceptibility to infections is a growing field. The identification of neutralizing autoantibodies against different cytokines has explained some aspects of the complex phenotypes of immune dysregulation in previously described IEIs, such as those affecting the alternative NF-κB pathway (106). In this update, we include autoantibodies directed against IL-27 underlying EBV infections (68), which phenocopy AR variants in IL27RA encoding one component of the IL-27R complex.

Somatic mutations as a phenocopy of IEI

Advances in sequencing techniques and analysis have enabled the identification of somatic variants as a cause of human immune diseases. Since IEIs have been defined as being caused by monogenic germline mutations, somatic mutations associated with disease are classified in Table 10 along with the phenocopies of IEI. Several somatic disorders have no germline disease equivalent. This is the case for VEXAS (an acronym for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome due to somatic mutation in UBA1 causing X-linked typically adult-onset immune dysregulation (107). In addition, there are diseases caused by either germline or somatic mutations including autoimmune lymphoproliferative syndrome due to FAS-FASL or RALD for which somatic mutations represent an important proportion of affected patients. All these disorders are included as phenocopies in Table 10. In this update, for several previously described AD autoinflammatory disorders, somatic mutations have been found to underlie a phenotype closely resembling that of germline variants affecting the same gene. Such is the case for somatic mutations in NLRP3, NOD2, TNFRSF1A, TNFAIP3, NLRC4, and MEFV (108, 109, 110, 111, 112, 113, 114) (indicated by ** in Tables 4 and 7). This growing list of immune disorders caused by somatic mutations underscores the need to consider variants detected at low allelic frequencies as possibly disease-causing, stressing the need for clinical laboratories to find ways to report these occurrences in addition to germline variants. We foresee that this list of somatic disorders resembling their IEI counterparts will increase with further advances in genetic sequencing and analysis techniques (115). In consideration of this, and to avoid redundancy, this committee has decided to denote such disorders throughout the manuscript to alert to the possibility of mosaicism as opposed to including them in Table 10 as different disorders.

Autoinflammation and immune dysregulation are at the forefront of novel discoveries blurring the borders between immunodeficiencies and rheumatology

Among the newly described genes, almost half (43%, 29/67) are either in the autoinflammatory or immune dysregulation tables. Autoimmune diseases affect around 10% of the population worldwide (116). These diseases have a complex etiology, where genetic and environmental factors interact, leading to a loss of tolerance against self-antigens, subsequent inflammation, and end-organ damage. B-cell dysregulation strongly contributes to the pathogenesis of several autoimmune diseases including SLE. The identification of new causes of monogenic lupus furthers our knowledge on how B cells are dysregulated and sheds light on new therapeutic targets. In this update, two novel gene defects are associated with monogenic lupus, namely, GOF variants in TLR7 (117) or UNC93B1 (23, 24). Remarkably, UNC93B1 is upstream of TLR7 and UNC93B1 GOF results in TLR7 hyperactivation, while TLR7 GOF variants result in aberrant survival of activated B cells. In addition, mutations in ERN1 (encoding IRE1α) disrupt XBP1 splicing and are associated with autoimmunity including SLE in one family member (66). In this update, we also include LACC1 as a monogenic cause of arthritis (64). Similar to COPA syndrome (118), monogenic arthritis due to biallelic LOF LACC1 variants is indistinguishable from polygenic arthritis. Thus, the identification of monogenic causes of arthritis may contribute to understanding pathophysiology and uncover new possibilities for precision medicine in rheumatology. As evidenced by the growing list of monogenic autoimmune disorders, the field of IEIs has become increasingly intertwined with rheumatology, underscoring the need to consider genetic analysis of patients with rheumatologic disease especially with, but not solely, onset in childhood. It is also important to note that the phenotypes of IEIs in general and specifically IEIs associated with autoimmunity and autoinflammation are increasingly overlapping.

Conclusions

In this update, the IUIS Expert Committee on IEI reports on 67 novel IEIs. These new gene defects bring the total number of IEIs to 559 (including four chromosomal deletion syndromes) resulting from variants in 508 genes (Fig. 1, A and B). The goals of the IUIS Expert Committee on IEI are to increase awareness, facilitate recognition, promote optimal treatment, and support research in the field of clinical immunology. The continuous increase in novel IEIs highlights the power of next-generation sequencing technologies with increased read depth also allowing for the detection of somatic mutations. Thorough and rigorous validation of candidate pathogenic variants enables us to (1) identify novel gene defects underlying human disease, (2) unveil mechanisms of disease pathogenesis, (3) define nonredundant functions of key genes in human immune cell development, host defense, and immune regulation, (4) expand the immunological and clinical phenotypes of IEIs, and (5) allow for future development of pathway- or gene-specific therapies. Collectively, the contributions of the researchers and scientists who discover novel IEIs will not only aid in diagnosing additional patients but also add to our fundamental knowledge of human immunology, as eloquently described in the inaugural Editorial for this journal by J.-L. Casanova (126).

Ethics approval

This work is a summary of recently reported genetic variants that represent novel IEIs. No human research studies were performed to produce this summary. Thus, no approvals by appropriate institutional review boards or human research ethics committees were required to undertake the preparation of this report.

Consent to Publish

The authors consent to publish the content of this summary. However, as noted above, as this is a summary of recently reported genetic variants that represent novel IEIs, we did not require consent to publish from participants.

The members of the Inborn Errors of Immunity Committee would like to thank the International Union of Immunological Societies.

This work was supported in part by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. S.G. Tangye is supported by an Investigator Grant (Level 3) awarded by the National Health and Medical Research Council of Australia. I. Meyts is a senior clinical investigator of FWO Vlaanderen (EBD-D8974-FKM) and also supported by Jeffrey Model Foundation. M.C. Poli is supported by ANID Regular Investigator Grant FONDECYT 1221802 and Jeffrey Modell Foundation.

Author contributions: M.C. Poli: conceptualization, data curation, formal analysis, methodology, and writing—original draft, review, and editing. I. Aksentijevich: conceptualization, investigation, and writing—review and editing. A.A. Bousfiha: writing—original draft, review, and editing. C. Cunningham-Rundles: resources and writing—review and editing. S. Hambleto: investigation and writing—review and editing. C. Klein: conceptualization, formal analysis, investigation, validation, and writing—review and editing. T. Morio: conceptualization, data curation, and validation. C. Picard: visualization and writing—original draft, review, and editing. A. Puel: writing—review and editing. N. Rezaei: conceptualization, data curation, investigation, methodology, supervision, validation, and writing—original draft, review, and editing. M.R.J. Seppänen: data curation, formal analysis, resources, validation, and writing—review and editing. R. Somech: data curation, formal analysis, investigation, supervision, and validation. H.C. Su: writing—review and editing. K.E. Sullivan: conceptualization, formal analysis, and writing—review and editing. T.R. Torgerson: data curation, investigation, and writing—review and editing. I. Meyts: conceptualization, data curation, formal analysis, investigation, methodology, supervision, validation, visualization, and writing—original draft, review, and editing. S.G. Tangye: conceptualization, data curation, investigation, project administration, supervision, and writing—original draft, review, and editing.

1.
Zhang
,
Q.
,
P.
Frange
,
S.
Blanche
, and
J.L.
Casanova
.
2017
.
Pathogenesis of infections in HIV-infected individuals: Insights from primary immunodeficiencies
.
Curr. Opin. Immunol.
48
:
122
133
.
2.
Rider
,
N.L.
,
A.
Truxton
,
T.
Ohrt
,
I.
Margolin-Katz
,
M.
Horan
,
H.
Shin
,
R.
Davila
,
V.
Tenembaum
,
J.
Quinn
,
V.
Modell
, et al
.
2024
.
Validating inborn error of immunity prevalence and risk with nationally representative electronic health record data
.
J. Allergy Clin. Immunol.
153
:
1704
1710
.
3.
Bousfiha
,
A.
,
L.
Jeddane
,
C.
Picard
,
W.
Al-Herz
,
F.
Ailal
,
T.
Chatila
,
C.
Cunningham-Rundles
,
A.
Etzioni
,
J.L.
Franco
,
S.M.
Holland
, et al
.
2020
.
Human inborn errors of immunity: 2019 update of the IUIS phenotypical classification
.
J. Clin. Immunol.
40
:
66
81
.
4.
Tangye
,
S.G.
,
W.
Al-Herz
,
A.
Bousfiha
,
T.
Chatila
,
C.
Cunningham-Rundles
,
A.
Etzioni
,
J.L.
Franco
,
S.M.
Holland
,
C.
Klein
,
T.
Morio
, et al
.
2020
.
Human inborn errors of immunity: 2019 update on the classification from the international union of immunological societies expert committee
.
J. Clin. Immunol.
40
:
24
64
.
5.
Casanova
,
J.L.
, and
L.
Abel
.
2018
.
Human genetics of infectious diseases: Unique insights into immunological redundancy
.
Semin. Immunol.
36
:
1
12
.
6.
Fischer
,
A.
, and
A.
Rausell
.
2018
.
What do primary immunodeficiencies tell us about the essentiality/redundancy of immune responses?
Semin. Immunol.
36
:
13
16
.
7.
Good
,
R.A.
1968
.
Experiments of nature in immunobiology
.
N. Engl. J. Med.
279
:
1344
1345
.
8.
Picard
,
C.
, and
A.
Fischer
.
2014
.
Contribution of high-throughput DNA sequencing to the study of primary immunodeficiencies
.
Eur. J. Immunol.
44
:
2854
2861
.
9.
Leiding
,
J.W.
, and
L.R.
Forbes
.
2019
.
Mechanism-based precision therapy for the treatment of primary immunodeficiency and primary immunodysregulatory diseases
.
J. Allergy Clin. Immunol. Pract.
7
:
761
773
.
10.
Ma
,
C.S.
, and
S.G.
Tangye
.
2019
.
Flow cytometric-based analysis of defects in lymphocyte differentiation and function due to inborn errors of immunity
.
Front. Immunol.
10
:
2108
.
11.
Casanova
,
J.L.
,
M.E.
Conley
,
S.J.
Seligman
,
L.
Abel
, and
L.D.
Notarangelo
.
2014
.
Guidelines for genetic studies in single patients: Lessons from primary immunodeficiencies
.
J. Exp. Med.
211
:
2137
2149
.
12.
Tangye
,
S.G.
,
W.
Al-Herz
,
A.
Bousfiha
,
C.
Cunningham-Rundles
,
J.L.
Franco
,
S.M.
Holland
,
C.
Klein
,
T.
Morio
,
E.
Oksenhendler
,
C.
Picard
, et al
.
2022
.
Human inborn errors of immunity: 2022 update on the classification from the international union of immunological Societies expert committee
.
J. Clin. Immunol.
42
:
1473
1507
.
13.
Frémond
,
M.L.
, and
N.
Nathan
.
2021
.
COPA syndrome, 5 years after: Where are we?
Joint Bone Spine
.
88
:
105070
.
14.
Delafontaine
,
S.
,
A.
Iannuzzo
,
T.M.
Bigley
,
B.
Mylemans
,
R.
Rana
,
P.
Baatsen
,
M.C.
Poli
,
D.
Rymen
,
K.
Jansen
,
D.
Mekahli
, et al
.
2024
.
Heterozygous mutations in the C-terminal domain of COPA underlie a complex autoinflammatory syndrome
.
J. Clin. Invest.
134
:e163604.
15.
Stewart
,
O.
,
C.
Gruber
,
H.E.
Randolph
,
R.
Patel
,
M.
Ramba
,
E.
Calzoni
,
L.H.
Huang
,
J.
Levy
,
S.
Buta
,
A.
Lee
, et al
.
2025
.
Monoallelic expression can govern penetrance of inborn errors of immunity
.
Nature
.
637
:
1186
1197
.
16.
Bucciol
,
G.
,
L.
Moens
,
A.
Corveleyn
,
A.
Dreesman
, and
I.
Meyts
.
2022
.
A novel kindred with MyD88 deficiency
.
J. Clin. Immunol.
42
:
885
888
.
17.
Csomos
,
K.
,
B.
Ujhazi
,
P.
Blazso
,
J.L.
Herrera
,
C.M.
Tipton
,
T.
Kawai
,
S.
Gordon
,
M.
Ellison
,
K.
Wu
,
M.
Stowell
, et al
.
2022
.
Partial RAG deficiency in humans induces dysregulated peripheral lymphocyte development and humoral tolerance defect with accumulation of T-bet+ B cells
.
Nat. Immunol.
23
:
1256
1272
.
18.
Haque
,
N.
,
T.
Kawai
,
B.D.
Ratnasinghe
,
J.B.
Wagenknecht
,
R.
Urrutia
,
L.D.
Notarangelo
, and
M.T.
Zimmermann
.
2023
.
RAG genomic variation causes autoimmune diseases through specific structure-based mechanisms of enzyme dysregulation
.
iScience
.
26
:
108040
.
19.
Bucciol
,
G.
,
S.
Delafontaine
,
I.
Meyts
, and
C.
Poli
.
2024
.
Inborn errors of immunity: A field without frontiers
.
Immunol. Rev.
322
:
15
27
.
20.
Fornes
,
O.
,
A.
Jia
,
H.S.
Kuehn
,
Q.
Min
,
U.
Pannicke
,
N.
Schleussner
,
R.
Thouenon
,
Z.
Yu
,
M.
de Los Angeles Astbury
,
C.M.
Biggs
, et al
.
2023
.
A multimorphic mutation in IRF4 causes human autosomal dominant combined immunodeficiency
.
Sci. Immunol.
8
:eade7953.
21.
Guerin
A.
,
G.
Kerner
,
N.
Marr
,
J.G.
Markle
,
F.
Fenollar
,
N.
Wong
,
S.
Boughorbel
,
D.T.
Avery
,
C.S.
Ma
,
S.
Bougarn
, et al
.
2018
.
IRF4 haploinsufficiency in a family with Whipple’s disease
.
Elife
.
7
:e32340.
22.
Thouenon
,
R.
,
L.
Chentout
,
N.
Moreno-Corona
,
L.
Poggi
,
E.P.
Lombardi
,
B.
Hoareau
,
Y.
Schmitt
,
C.
Lagresle-Peyrou
,
J.
Bustamante
,
I.
André
, et al
.
2023
.
A neomorphic mutation in the interferon activation domain of IRF4 causes a dominant primary immunodeficiency
.
J. Exp. Med.
220
:e20221292.
23.
Wolf
,
C.
,
E.L.
Lim
,
M.
Mokhtari
,
B.
Kind
,
A.
Odainic
,
E.
Lara-Villacanas
,
S.
Koss
,
S.
Mages
,
K.
Menzel
,
K.
Engel
, et al
.
2024
.
UNC93B1 variants underlie TLR7-dependent autoimmunity
.
Sci. Immunol.
9
:eadi9769.
24.
David
,
C.
,
C.A.
Arango-Franco
,
M.
Badonyi
,
J.
Fouchet
,
G.I.
Rice
,
B.
Didry-Barca
,
L.
Maisonneuve
,
L.
Seabra
,
R.
Kechiche
,
C.
Masson
, et al
.
2024
.
Gain-of-function human UNC93B1 variants cause systemic lupus erythematosus and chilblain lupus
.
J. Exp. Med.
221
:e20232066.
25.
Al-Azab
,
M.
,
E.
Idiiatullina
,
Z.
Liu
,
M.
Lin
,
K.
Hrovat-Schaale
,
H.
Xian
,
J.
Zhu
,
M.
Yang
,
B.
Lu
,
Z.
Zhao
, et al
.
2024
.
Genetic variants in UNC93B1 predispose to childhood-onset systemic lupus erythematosus
.
Nat. Immunol.
25
:
969
980
.
26.
Kostel Bal
,
S.
,
S.
Giuliani
,
J.
Block
,
P.
Repiscak
,
C.
Hafemeister
,
T.
Shahin
,
N.
Kasap
,
B.
Ransmayr
,
Y.
Miao
,
C.
van de Wetering
, et al
.
2023
.
Biallelic NFATC1 mutations cause an inborn error of immunity with impaired CD8+ T-cell function and perturbed glycolysis
.
Blood
.
142
:
827
845
.
27.
Parry
,
D.A.
,
L.
Tamayo-Orrego
,
P.
Carroll
,
J.A.
Marsh
,
P.
Greene
,
O.
Murina
,
C.
Uggenti
,
A.
Leitch
,
R.
Káposzta
,
G.
Merő
, et al
.
2020
.
PRIM1 deficiency causes a distinctive primordial dwarfism syndrome
.
Genes Dev.
34
:
1520
1533
.
28.
Toskov
,
V.
,
P.
Kaiser-Labusch
,
M.A.
Lee-Kirsch
,
PRIM1 study group
,
S.
Ehl
, and
O.
Wegehaupt
.
2024
.
Variable syndromic immunodeficiency in patients with biallelic PRIM1 mutations
.
J. Clin. Immunol.
44
:
129
.
29.
Ghosh
,
R.
,
M.
Bosticardo
,
S.
Singh
,
M.
Similuk
,
O.M.
Delmonte
,
F.
Pala
,
C.
Peng
,
C.
Jodarski
,
M.D.
Keller
,
I.K.
Chinn
, et al
.
2022
.
FOXI3 haploinsufficiency contributes to low T-cell receptor excision circles and T-cell lymphopenia
.
J. Allergy Clin. Immunol.
150
:
1556
1562
.
30.
Riestra
,
M.R.
,
B.A.
Pillay
,
M.
Willemsen
,
V.
Kienapfel
,
L.
Ehlers
,
S.
Delafontaine
,
A.
Pinton
,
M.
Wouters
,
A.
Hombrouck
,
K.
Sauer
, et al
.
2023
.
Human autosomal recessive DNA polymerase delta 3 deficiency presenting as Omenn syndrome
.
J. Clin. Immunol.
44
:
2
.
31.
Chen
,
R.
,
E.
Lukianova
,
I.S.
van der Loeff
,
J.S.
Spegarova
,
J.D.P.
Willet
,
K.D.
James
,
E.J.
Ryder
,
H.
Griffin
,
H.
Ijspeert
,
A.
Gajbhiye
, et al
.
2024
. NUDCD3
deficiency disrupts V(D)J recombination to cause SCID and Omenn syndrome
.
Sci. Immunol.
9
:eade5705.
32.
van der Made
,
C.I.
,
S.
Kersten
,
O.
Chorin
,
K.R.
Engelhardt
,
G.
Ramakrishnan
,
H.
Griffin
,
I.
Schim van der Loeff
,
H.
Venselaar
,
A.R.
Rothschild
,
M.
Segev
, et al
.
2024
.
Expanding the PRAAS spectrum: De novo mutations of immunoproteasome subunit β-type 10 in six infants with SCID-Omenn syndrome
.
Am. J. Hum. Genet.
111
:
791
804
.
33.
Mohajeri
,
A.
,
M.
Vaseghi-Shanjani
,
J.A.
Rosenfeld
,
G.X.
Yang
,
H.
Lu
,
M.
Sharma
,
S.
Lin
,
A.
Salman
,
M.
Waqas
,
M.
Sababi Azamian
, et al
.
2023
.
Dominant negative variants in IKZF2 cause ICHAD syndrome, a new disorder characterised by immunodysregulation, craniofacial anomalies, hearing impairment, athelia and developmental delay
.
J. Med. Genet.
60
:
1092
1104
.
34.
Conte
,
M.I.
,
M.C.
Poli
,
A.
Taglialatela
,
G.
Leuzzi
,
I.K.
Chinn
,
S.A.
Salinas
,
E.
Rey-Jurado
,
N.
Olivares
,
L.
Veramendi-Espinoza
,
A.
Ciccia
, et al
.
2022
.
Partial loss-of-function mutations in GINS4 lead to NK cell deficiency with neutropenia
.
JCI Insight
.
7
:e154948.
35.
Sharma
,
M.
,
D.
Leung
,
M.
Momenilandi
,
L.C.W.
Jones
,
L.
Pacillo
,
A.E.
James
,
J.R.
Murrell
,
S.
Delafontaine
,
J.
Maimaris
,
M.
Vaseghi-Shanjani
, et al
.
2023
.
Human germline heterozygous gain-of-function STAT6 variants cause severe allergic disease
.
J. Exp. Med.
220
:e20221755.
36.
Baris
,
S.
,
M.
Benamar
,
Q.
Chen
,
M.C.
Catak
,
M.
Martínez-Blanco
,
M.
Wang
,
J.
Fong
,
M.J.
Massaad
,
A.P.
Sefer
,
A.
Kara
, et al
.
2023
.
Severe allergic dysregulation due to a gain of function mutation in the transcription factor STAT6
.
J. Allergy Clin. Immunol.
152
:
182
194.e7
.
37.
Gök
,
V.
,
Ş.
Erdem
,
Y.
Haliloğlu
,
A.
Bişgin
,
S.
Belkaya
,
K.E.
Başaran
,
M.F.
Canatan
,
A.
Özcan
,
E.
Yılmaz
,
C.
Acıpayam
, et al
.
2023
.
Immunodeficiency associated with a novel functionally defective variant of SLC19A1 benefits from folinic acid treatment
.
Genes Immun.
24
:
12
20
.
38.
Saba
,
J.D.
,
N.
Keller
,
J.Y.
Wang
,
F.
Tang
,
A.
Slavin
, and
Y.
Shen
.
2021
.
Genotype/phenotype interactions and first steps toward targeted therapy for sphingosine phosphate lyase insufficiency syndrome
.
Cell Biochem. Biophys.
79
:
547
559
.
39.
Tran
,
P.
,
M.
Jamee
,
Z.
Pournasiri
,
Z.
Chavoshzadeh
, and
K.E.
Sullivan
.
2023
.
SGPL1 deficiency: Nephrotic syndrome with lymphopenia
.
J. Clin. Immunol.
43
:
72
75
.
40.
Materna
,
M.
,
O.M.
Delmonte
,
M.
Bosticardo
,
M.
Momenilandi
,
P.E.
Conrey
,
B.
Charmeteau-De Muylder
,
C.
Bravetti
,
R.
Bellworthy
,
A.
Cederholm
,
F.
Staels
, et al
.
2024
.
The immunopathological landscape of human pre-TCRα deficiency: From rare to common variants
.
Science
.
383
:eadh4059.
41.
Momenilandi
,
M.
,
R.
Lévy
,
S.
Sobrino
,
J.
Li
,
C.
Lagresle-Peyrou
,
H.
Esmaeilzadeh
,
A.
Fayand
,
C.
Le Floc’h
,
A.
Guérin
,
E.
Della Mina
, et al
.
2024
.
FLT3L governs the development of partially overlapping hematopoietic lineages in humans and mice
.
Cell
.
187
:
2817
2837.e31
.
42.
Neumann
,
J.
,
E.
Van Nieuwenhove
,
L.E.
Terry
,
F.
Staels
,
T.R.
Knebel
,
K.
Welkenhuyzen
,
K.
Ahmadzadeh
,
M.R.
Baker
,
M.
Gerbaux
,
M.
Willemsen
, et al
.
2023
.
Disrupted Ca2+ homeostasis and immunodeficiency in patients with functional IP3 receptor subtype 3 defects
.
Cell. Mol. Immunol.
20
:
11
25
.
43.
De Somer
,
L.
,
C.
Wouters
,
M.A.
Morren
,
R.
De Vos
,
J.
Van Den Oord
,
K.
Devriendt
, and
I.
Meyts
.
2010
.
Granulomatous skin lesions complicating varicella infection in a patient with Rothmund-Thomson syndrome and immune deficiency: Case report
.
Orphanet J. Rare Dis.
5
:
37
.
44.
Broom
,
M.A.
,
L.L.
Wang
,
S.K.
Otta
,
A.P.
Knutsen
,
E.
Siegfried
,
J.R.
Batanian
,
M.E.
Kelly
, and
M.
Shah
.
2006
.
Successful umbilical cord blood stem cell transplantation in a patient with Rothmund-Thomson syndrome and combined immunodeficiency
.
Clin. Genet.
69
:
337
343
.
45.
Schepers
,
D.
,
G.
Tortora
,
H.
Morisaki
,
G.
MacCarrick
,
M.
Lindsay
,
D.
Liang
,
S.G.
Mehta
,
J.
Hague
,
J.
Verhagen
,
I.
van de Laar
, et al
.
2018
.
A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3
.
Hum. Mutat.
39
:
621
634
.
46.
Chesneau
,
B.
,
T.
Edouard
,
Y.
Dulac
,
H.
Colineaux
,
M.
Langeois
,
N.
Hanna
,
C.
Boileau
,
P.
Arnaud
,
N.
Chassaing
,
S.
Julia
, et al
.
2020
.
Clinical and genetic data of 22 new patients with SMAD3 pathogenic variants and review of the literature
.
Mol. Genet. Genomic Med.
8
:e1132.
47.
Gouda
,
P.
,
R.
Kay
,
M.
Habib
,
A.
Aziz
,
E.
Aziza
, and
R.
Welsh
.
2022
.
Clinical features and complications of Loeys-Dietz syndrome: A systematic review
.
Int. J. Cardiol.
362
:
158
167
.
48.
Kaiser
,
F.M.P.
,
S.
Gruenbacher
,
M.R.
Oyaga
,
E.
Nio
,
M.
Jaritz
,
Q.
Sun
,
W.
van der Zwaag
,
E.
Kreidl
,
L.M.
Zopf
,
V.A.S.H.
Dalm
, et al
.
2022
.
Biallelic PAX5 mutations cause hypogammaglobulinemia, sensorimotor deficits, and autism spectrum disorder
.
J. Exp. Med.
219
:e20220498.
49.
Saettini
,
F.
,
F.
Guerra
,
G.
Fazio
,
C.
Bugarin
,
H.J.
McMillan
,
A.
Ohtake
,
A.
Ardissone
,
M.
Itoh
,
S.
Giglio
,
G.
Cappuccio
, et al
.
2023
.
Antibody deficiency in patients with biallelic KARS1 mutations
.
J. Clin. Immunol.
43
:
2115
2125
.
50.
Saettini
,
F.
,
F.
Guerra
,
M.
Mauri
,
C.G.
Salter
,
M.P.
Adam
,
D.
Adams
,
E.L.
Baple
,
E.
Barredo
,
S.
Bhatia
,
A.
Borkhardt
, et al
.
2024
.
Biallelic PI4KA mutations disrupt B-cell metabolism and cause B-cell lymphopenia and hypogammaglobulinemia
.
J. Clin. Immunol.
45
:
15
.
51.
Johnson
,
M.B.
,
M.
Ogishi
,
C.
Domingo-Vila
,
E.
De Franco
,
M.N.
Wakeling
,
Z.
Imane
,
B.
Resnick
,
E.
Williams
,
R.P.
Galão
,
R.
Caswell
, et al
.
2024
.
Human inherited PD-L1 deficiency is clinically and immunologically less severe than PD-1 deficiency
.
J. Exp. Med.
221
:e20231704.
52.
Mishra
,
H.
,
C.
Schlack-Leigers
,
E.L.
Lim
,
O.
Thieck
,
T.
Magg
,
J.
Raedler
,
C.
Wolf
,
C.
Klein
,
H.
Ewers
,
M.A.
Lee-Kirsch
, et al
.
2024
.
Disrupted degradative sorting of TLR7 is associated with human lupus
.
Sci. Immunol.
9
:eadi9575.
53.
Stremenova Spegarova
,
J.
,
P.
Sinnappurajar
,
D.
Al Julandani
,
R.
Navickas
,
H.
Griffin
,
M.
Ahuja
,
A.
Grainger
,
K.
Livingstone
,
G.I.
Rice
,
F.
Sutherland
, et al
.
2024
.
A de novo TLR7 gain-of-function mutation causing severe monogenic lupus in an infant
.
J. Clin. Invest.
134
:e179193.
54.
Rae
,
W.
,
J.M.
Sowerby
,
D.
Verhoeven
,
M.
Youssef
,
P.
Kotagiri
,
N.
Savinykh
,
E.L.
Coomber
,
A.
Boneparth
,
A.
Chan
,
C.
Gong
, et al
.
2022
.
Immunodeficiency, autoimmunity, and increased risk of B cell malignancy in humans with TRAF3 mutations
.
Sci. Immunol.
7
:eabn3800.
55.
Li
,
X.
,
W.
Sun
,
M.
Huang
,
L.
Gong
,
X.
Zhang
,
L.
Zhong
,
V.
Calderon
,
Z.
Bian
,
Y.
He
,
W.K.
Suh
, et al
.
2024
.
Deficiency of CBL and CBLB ubiquitin ligases leads to hyper T follicular helper cell responses and lupus by reducing BCL6 degradation
.
Immunity
.
57
:
1603
1617.e7
.
56.
Tao
,
P.
,
X.
Han
,
Q.
Wang
,
S.
Wang
,
J.
Zhang
,
L.
Liu
,
X.
Fan
,
C.
Liu
,
M.
Liu
,
L.
Guo
, et al
.
2023
.
A gain-of-function variation in PLCG1 causes a new immune dysregulation disease
.
J. Allergy Clin. Immunol.
152
:
1292
1302
.
57.
Blombery
,
P.
,
V.
Pazhakh
,
A.S.
Albuquerque
,
J.
Maimaris
,
L.
Tu
,
B.
Briones Miranda
,
F.
Evans
,
E.R.
Thompson
,
B.
Carpenter
,
I.
Proctor
, et al
.
2023
.
Biallelic deleterious germline SH2B3 variants cause a novel syndrome of myeloproliferation and multi-organ autoimmunity
.
EJHaem
.
4
:
463
469
.
58.
Sindram
,
E.
,
A.
Caballero-Oteyza
,
N.
Kogata
,
S.
Chor Mei Huang
,
Z.
Alizadeh
,
L.
Gámez-Díaz
,
M.R.
Fazlollhi
,
X.
Peng
,
B.
Grimbacher
,
M.
Way
, and
M.
Proietti
.
2023
.
ARPC5 deficiency leads to severe early-onset systemic inflammation and mortality
.
Dis. Model. Mech.
16
:
dmm050145
.
59.
Erman
,
B.
,
S.K.
Bal
,
Ç.
Aydoğmuş
,
G.Z.
Ersoy
, and
K.
Boztug
.
2024
.
A novel homozygous six base pair deletion found in the NFATC2 gene in a patient with EBV-associated lymphoproliferation
.
J. Clin. Immunol.
44
:
74
.
60.
Sharma
,
M.
,
M.P.
Fu
,
H.Y.
Lu
,
A.A.
Sharma
,
B.P.
Modi
,
C.
Michalski
,
S.
Lin
,
J.
Dalmann
,
A.
Salman
,
K.L.
Del Bel
, et al
.
2022
.
Human complete NFAT1 deficiency causes a triad of joint contractures, osteochondromas, and B-cell malignancy
.
Blood
.
140
:
1858
1874
.
61.
Block
,
J.
,
C.
Rashkova
,
I.
Castanon
,
S.
Zoghi
,
J.
Platon
,
R.C.
Ardy
,
M.
Fujiwara
,
B.
Chaves
,
R.
Schoppmeyer
,
C.I.
van der Made
, et al
.
2023
.
Systemic inflammation and normocytic anemia in DOCK11 deficiency
.
N. Engl. J. Med.
389
:
527
539
.
62.
Boussard
,
C.
,
L.
Delage
,
T.
Gajardo
,
A.
Kauskot
,
M.
Batignes
,
N.
Goudin
,
M.C.
Stolzenberg
,
C.
Brunaud
,
P.
Panikulam
,
Q.
Riller
, et al
.
2023
.
DOCK11 deficiency in patients with X-linked actinopathy and autoimmunity
.
Blood
.
141
:
2713
2726
.
63.
Kubo
,
S.
,
J.M.
Fritz
,
H.M.
Raquer-McKay
,
R.
Kataria
,
I.
Vujkovic-Cvijin
,
A.
Al-Shaibi
,
Y.
Yao
,
L.
Zheng
,
J.
Zou
,
A.D.
Waldman
, et al
.
2022
.
Congenital iRHOM2 deficiency causes ADAM17 dysfunction and environmentally directed immunodysregulatory disease
.
Nat. Immunol.
23
:
75
85
.
64.
Omarjee
,
O.
,
A.L.
Mathieu
,
G.
Quiniou
,
M.
Moreews
,
M.
Ainouze
,
C.
Frachette
,
I.
Melki
,
C.
Dumaine
,
M.
Gerfaud-Valentin
,
A.
Duquesne
, et al
.
2021
.
LACC1 deficiency links juvenile arthritis with autophagy and metabolism in macrophages
.
J. Exp. Med.
218
:e20201006.
65.
Wakil
,
S.M.
,
D.M.
Monies
,
M.
Abouelhoda
,
N.
Al-Tassan
,
H.
Al-Dusery
,
E.A.
Naim
,
B.
Al-Younes
,
J.
Shinwari
,
F.A.
Al-Mohanna
,
B.F.
Meyer
, and
S.
Al-Mayouf
.
2015
.
Association of a mutation in LACC1 with a monogenic form of systemic juvenile idiopathic arthritis
.
Arthritis Rheumatol.
67
:
288
295
.
66.
Reuschlé
,
Q.
,
L.
Van Heddegem
,
V.
Bosteels
,
M.
Moncan
,
S.
Depauw
,
N.
Wadier
,
S.
Maréchal
,
C.
De Nolf
,
V.
Delgado
,
Y.
Messai
, et al
.
2024
.
Loss of function of XBP1 splicing activity of IRE1α favors B cell tolerance breakdown
.
J. Autoimmun.
142
:
103152
.
67.
Delage
,
L.
,
F.
Carbone
,
Q.
Riller
,
J.L.
Zachayus
,
E.
Kerbellec
,
A.
Buzy
,
M.C.
Stolzenberg
,
M.
Luka
,
C.
de Cevins
,
G.
Kalouche
, et al
.
2023
.
NBEAL2 deficiency in humans leads to low CTLA-4 expression in activated conventional T cells
.
Nat. Commun.
14
:
3728
.
68.
Martin
,
E.
,
S.
Winter
,
C.
Garcin
,
K.
Tanita
,
A.
Hoshino
,
C.
Lenoir
,
B.
Fournier
,
M.
Migaud
,
D.
Boutboul
,
M.
Simonin
, et al
.
2024
.
Role of IL-27 in Epstein-Barr virus infection revealed by IL-27RA deficiency
.
Nature
.
628
:
620
629
.
69.
Fournier
,
B.
,
A.
Hoshino
,
J.
Bruneau
,
C.
Bachelet
,
M.
Fusaro
,
R.
Klifa
,
R.
Lévy
,
C.
Lenoir
,
C.
Soudais
,
C.
Picard
, et al
.
2022
.
Inherited TNFSF9 deficiency causes broad Epstein-Barr virus infection with EBV+ smooth muscle tumors
.
J. Exp. Med.
219
:e20211682.
70.
Harapas
,
C.R.
,
K.S.
Robinson
,
K.
Lay
,
J.
Wong
,
R.
Moreno Traspas
,
N.
Nabavizadeh
,
A.
Rass-Rothschild
,
B.
Boisson
,
S.B.
Drutman
,
P.
Laohamonthonkul
, et al
.
2022
.
DPP9 deficiency: An inflammasomopathy that can be rescued by lowering NLRP1/IL-1 signaling
.
Sci. Immunol.
7
:eabi4611.
71.
Yao
,
Y.
,
P.
Du Jiang
,
B.N.
Chao
,
D.
Cagdas
,
S.
Kubo
,
A.
Balasubramaniyam
,
Y.
Zhang
,
B.
Shadur
,
A.
NaserEddin
,
L.R.
Folio
, et al
.
2022
.
GIMAP6 regulates autophagy, immune competence, and inflammation in mice and humans
.
J. Exp. Med.
219
:e20201405.
72.
Jeanpierre
,
M.
,
J.
Cognard
,
M.
Tusseau
,
Q.
Riller
,
L.C.
Bui
,
J.
Berthelet
,
A.
Laurent
,
E.
Crickx
,
M.
Parlato
,
M.C.
Stolzenberg
, et al
.
2024
.
Haploinsufficiency in PTPN2 leads to early-onset systemic autoimmunity from Evans syndrome to lupus
.
J. Exp. Med.
221
:e20232337.
73.
Willemsen
,
M.
,
A.
De Visscher
,
J.
Filtjens
,
I.
Meyts
,
P.
Matthys
,
S.
Humblet-Baron
, and
A.
Liston
.
2024
.
An immature NK cell compartment in functional DBF4 deficiency
.
J. Clin. Immunol.
44
:
146
.
74.
Linder
,
M.I.
,
Y.
Mizoguchi
,
S.
Hesse
,
G.
Csaba
,
M.
Tatematsu
,
M.
Łyszkiewicz
,
N.
Ziȩtara
,
T.
Jeske
,
M.
Hastreiter
,
M.
Rohlfs
, et al
.
2023
.
Human genetic defects in SRP19 and SRPRA cause severe congenital neutropenia with distinctive proteome changes
.
Blood
.
141
:
645
658
.
75.
Neehus
,
A.L.
,
B.
Carey
,
M.
Landekic
,
P.
Panikulam
,
G.
Deutsch
,
M.
Ogishi
,
C.A.
Arango-Franco
,
Q.
Philippot
,
M.
Modaresi
,
I.
Mohammadzadeh
, et al
.
2024
.
Human inherited CCR2 deficiency underlies progressive polycystic lung disease
.
Cell
.
187
:
390
408.e23
.
76.
Rosain
,
J.
,
A.L.
Neehus
,
J.
Manry
,
R.
Yang
,
J.
Le Pen
,
W.
Daher
,
Z.
Liu
,
Y.H.
Chan
,
N.
Tahuil
,
Ö.
Türel
, et al
.
2023
.
Human IRF1 governs macrophagic IFN-γ immunity to mycobacteria
.
Cell
.
186
:
621
645.e33
.
77.
Bohlen
,
J.
,
Q.
Zhou
,
Q.
Philippot
,
M.
Ogishi
,
D.
Rinchai
,
T.
Nieminen
,
S.
Seyedpour
,
N.
Parvaneh
,
N.
Rezaei
,
N.
Yazdanpanah
, et al
.
2023
.
Human MCTS1-dependent translation of JAK2 is essential for IFN-γ immunity to mycobacteria
.
Cell
.
186
:
5114
5134.e27
.
78.
Lee
,
D.
,
J.
Le Pen
,
A.
Yatim
,
B.
Dong
,
Y.
Aquino
,
M.
Ogishi
,
R.
Pescarmona
,
E.
Talouarn
,
D.
Rinchai
,
P.
Zhang
, et al
.
2023
.
Inborn errors of OAS-RNase L in SARS-CoV-2-related multisystem inflammatory syndrome in children
.
Science
.
379
:eabo3627.
79.
Liu
,
Z.
,
E.J.
Garcia Reino
,
O.
Harschnitz
,
H.
Guo
,
Y.H.
Chan
,
N.V.
Khobrekar
,
M.L.
Hasek
,
K.
Dobbs
,
D.
Rinchai
,
M.
Materna
, et al
.
2023
.
Encephalitis and poor neuronal death-mediated control of herpes simplex virus in human inherited RIPK3 deficiency
.
Sci. Immunol.
8
:eade2860.
80.
Li
,
Y.
,
Z.
Yu
,
M.
Schenk
,
I.
Lagovsky
,
D.
Illig
,
C.
Walz
,
M.
Rohlfs
,
R.
Conca
,
A.M.
Muise
,
S.B.
Snapper
, et al
.
2023
.
Human MD2 deficiency-an inborn error of immunity with pleiotropic features
.
J. Allergy Clin. Immunol.
151
:
791
796.e7
.
81.
Capitani
,
M.
,
A.A.
Al-Shaibi
,
S.
Pandey
,
L.
Gartner
,
H.
Taylor
,
S.Z.
Hubrack
,
N.
Agrebi
,
M.J.
Al-Mohannadi
,
S.
Al Kaabi
,
T.
Vogl
, et al
.
2023
.
Biallelic TLR4 deficiency in humans
.
J. Allergy Clin. Immunol.
151
:
783
790.e5
.
82.
Naesens
,
L.
,
S.
Muppala
,
D.
Acharya
,
J.
Nemegeer
,
D.
Bogaert
,
J.H.
Lee
,
K.
Staes
,
V.
Debacker
,
P.
De Bleser
,
M.
De Bruyne
, et al
.
2022
.
GTF3A mutations predispose to herpes simplex encephalitis by disrupting biogenesis of the host-derived RIG-I ligand RNA5SP141
.
Sci. Immunol.
7
:eabq4531.
83.
Reyahi
,
A.
,
M.
Studahl
,
M.K.
Skouboe
,
S.
Fruhwürth
,
R.
Narita
,
F.
Ren
,
M.
Bjerhem Viklund
,
M.B.
Iversen
,
M.
Christiansen
,
A.
Svensson
, et al
.
2023
.
An IKBKE variant conferring functional cGAS/STING pathway deficiency and susceptibility to recurrent HSV-2 meningitis
.
JCI Insight
.
8
:e173066.
84.
Uggenti
,
C.
,
A.
Lepelley
,
M.
Depp
,
A.P.
Badrock
,
M.P.
Rodero
,
M.T.
El-Daher
,
G.I.
Rice
,
S.
Dhir
,
A.P.
Wheeler
,
A.
Dhir
, et al
.
2020
.
cGAS-mediated induction of type I interferon due to inborn errors of histone pre-mRNA processing
.
Nat. Genet.
52
:
1364
1372
.
85.
Naesens
,
L.
,
J.
Nemegeer
,
F.
Roelens
,
L.
Vallaeys
,
M.
Meuwissen
,
K.
Janssens
,
P.
Verloo
,
B.
Ogunjimi
,
D.
Hemelsoet
,
L.
Hoste
, et al
.
2022
.
Mutations in RNU7-1 weaken secondary RNA structure, induce MCP-1 and CXCL10 in CSF, and result in Aicardi-Goutières syndrome with severe end-organ involvement
.
J. Clin. Immunol.
42
:
962
974
.
86.
Baghdassarian
,
H.
,
S.A.
Blackstone
,
O.S.
Clay
,
R.
Philips
,
B.
Matthiasardottir
,
M.
Nehrebecky
,
V.K.
Hua
,
R.
McVicar
,
Y.
Liu
,
S.M.
Tucker
, et al
.
2023
.
Variant STAT4 and response to ruxolitinib in an autoinflammatory syndrome
.
N. Engl. J. Med.
388
:
2241
2252
.
87.
Berner
,
J.
,
C.
van de Wetering
,
R.
Jimenez Heredia
,
C.
Rashkova
,
S.
Ferdinandusse
,
J.
Koster
,
J.G.
Weiss
,
A.
Frohne
,
S.
Giuliani
,
H.R.
Waterham
, et al
.
2023
.
Phosphomevalonate kinase deficiency expands the genetic spectrum of systemic autoinflammatory diseases
.
J. Allergy Clin. Immunol.
152
:
1025
1031.e2
.
88.
Kozycki
,
C.T.
,
S.
Kodati
,
L.
Huryn
,
H.
Wang
,
B.M.
Warner
,
P.
Jani
,
D.
Hammoud
,
M.S.
Abu-Asab
,
Y.
Jittayasothorn
,
M.J.
Mattapallil
, et al
.
2022
.
Gain-of-function mutations in ALPK1 cause an NF-κB-mediated autoinflammatory disease: Functional assessment, clinical phenotyping and disease course of patients with ROSAH syndrome
.
Ann. Rheum. Dis.
81
:
1453
1464
.
89.
Louvrier
,
C.
,
E.
El Khouri
,
M.
Grall Lerosey
,
P.
Quartier
,
A.M.
Guerrot
,
B.
Bader Meunier
,
J.
Chican
,
M.
Mohammad
,
E.
Assrawi
,
A.
Daskalopoulou
, et al
.
2023
.
De novo gain-of-function variations in LYN associated with an early-onset systemic autoinflammatory disorder
.
Arthritis Rheumatol.
75
:
468
474
.
90.
Oda
,
H.
,
K.
Manthiram
,
P.P.
Chavan
,
E.
Rieser
,
Ö.
Veli
,
Ö.
Kaya
,
C.
Rauch
,
S.
Nakabo
,
H.S.
Kuehn
,
M.
Swart
, et al
.
2024
.
Biallelic human SHARPIN loss of function induces autoinflammation and immunodeficiency
.
Nat. Immunol.
25
:
764
777
.
91.
Staels
,
F.
,
L.
Bücken
,
L.
De Vuyst
,
M.
Willemsen
,
E.
Van Nieuwenhove
,
M.
Gerbaux
,
J.
Neumann
,
V.
Malviya
,
L.
Van Meerbeeck
,
J.
Haughton
, et al
.
2024
.
OTULIN haploinsufficiency predisposes to environmentally directed inflammation
.
Front. Immunol.
15
:
983686
.
92.
Spaan
,
A.N.
2024
.
OTULIN and Muller’s morphs
.
J. Exp. Med.
221
:e20240418.
93.
Moriya
,
K.
,
T.
Nakano
,
Y.
Honda
,
M.
Tsumura
,
M.
Ogishi
,
M.
Sonoda
,
M.
Nishitani-Isa
,
T.
Uchida
,
M.
Hbibi
,
Y.
Mizoguchi
, et al
.
2023
.
Human RELA dominant-negative mutations underlie type I interferonopathy with autoinflammation and autoimmunity
.
J. Exp. Med.
220
:e20212276.
94.
Hirschenberger
,
M.
,
A.
Lepelley
,
U.
Rupp
,
S.
Klute
,
V.
Hunszinger
,
L.
Koepke
,
V.
Merold
,
B.
Didry-Barca
,
F.
Wondany
,
T.
Bergner
, et al
.
2023
.
ARF1 prevents aberrant type I interferon induction by regulating STING activation and recycling
.
Nat. Commun.
14
:
6770
.
95.
Immonen
,
A.T.
,
S.
Kawan
,
M.
Vesaluoma
,
J.M.
Heiskanen
,
C.
Taipale
,
M.
Koskinen
,
A.
Majander
,
T.T.
Kivelä
, and
J.A.
Turunen
.
2022
.
Clinical spectrum and geographic distribution of keratitis fugax hereditaria caused by the pathogenic variant c.61G>C in NLRP3
.
Am. J. Ophthalmol.
236
:
309
318
.
96.
Kawan
,
S.
,
M.P.
Backlund
,
A.T.
Immonen
,
T.T.
Kivelä
, and
J.A.
Turunen
.
2024
.
Functional consequences of pathogenic variant c.61G>C in the inflammasome gene NLRP3 underlying keratitis fugax hereditaria
.
Br. J. Ophthalmol.
108
:
323
328
.
97.
Kermasson
,
L.
,
D.
Churikov
,
A.
Awad
,
R.
Smoom
,
E.
Lainey
,
F.
Touzot
,
S.
Audebert-Bellanger
,
S.
Haro
,
L.
Roger
,
E.
Costa
, et al
.
2022
.
Inherited human Apollo deficiency causes severe bone marrow failure and developmental defects
.
Blood
.
139
:
2427
2440
.
98.
Dos Santos
,
R.S.
,
M.
Daures
,
A.
Philippi
,
S.
Romero
,
L.
Marselli
,
P.
Marchetti
,
V.
Senée
,
D.
Bacq
,
C.
Besse
,
B.
Baz
, et al
.
2017
.
dUTPase (DUT) is mutated in a novel monogenic syndrome with diabetes and bone marrow failure
.
Diabetes
.
66
:
1086
1096
.
99.
Takagi
,
M.
,
A.
Hoshino
,
K.
Bousset
,
J.
Röddecke
,
H.L.
Martin
,
I.
Folcut
,
D.
Tomomasa
,
X.
Yang
,
J.
Kobayashi
,
N.
Sakata
, et al
.
2023
.
Bone marrow failure and immunodeficiency associated with human RAD50 variants
.
J. Clin. Immunol.
43
:
2136
2145
.
100.
Gruber
,
C.N.
,
J.J.A.
Calis
,
S.
Buta
,
G.
Evrony
,
J.C.
Martin
,
S.A.
Uhl
,
R.
Caron
,
L.
Jarchin
,
D.
Dunkin
,
R.
Phelps
, et al
.
2020
.
Complex autoinflammatory syndrome unveils fundamental principles of JAK1 kinase transcriptional and biochemical function
.
Immunity
.
53
:
672
684.e11
.
101.
Bellelli
,
R.
, and
S.J.
Boulton
.
2021
.
Spotlight on the replisome: Aetiology of DNA replication-associated genetic diseases
.
Trends Genet.
37
:
317
336
.
102.
Mace
,
E.M.
,
S.
Paust
,
M.I.
Conte
,
R.M.
Baxley
,
M.M.
Schmit
,
S.L.
Patil
,
N.C.
Guilz
,
M.
Mukherjee
,
A.E.
Pezzi
,
J.
Chmielowiec
, et al
.
2020
.
Human NK cell deficiency as a result of biallelic mutations in MCM10
.
J. Clin. Invest.
130
:
5272
5286
.
103.
Baxley
,
R.M.
,
W.
Leung
,
M.M.
Schmit
,
J.P.
Matson
,
L.
Yin
,
M.K.
Oram
,
L.
Wang
,
J.
Taylor
,
J.
Hedberg
,
C.B.
Rogers
, et al
.
2021
.
Bi-allelic MCM10 variants associated with immune dysfunction and cardiomyopathy cause telomere shortening
.
Nat. Commun.
12
:
1626
.
104.
Régnier
,
P.
,
M.
Vetillard
,
A.
Bansard
,
E.
Pierre
,
X.
Li
,
N.
Cagnard
,
E.L.
Gautier
,
P.
Guermonprez
,
B.
Manoury
,
K.
Podsypanina
, and
G.
Darrasse-Jèze
.
2023
.
FLT3L-dependent dendritic cells control tumor immunity by modulating Treg and NK cell homeostasis
.
Cell Rep. Med.
4
:
101256
.
105.
Sikder
,
M.A.A.
,
R.B.
Rashid
,
T.
Ahmed
,
I.
Sebina
,
D.R.
Howard
,
M.A.
Ullah
,
M.M.
Rahman
,
J.P.
Lynch
,
B.
Curren
,
R.B.
Werder
, et al
.
2023
.
Maternal diet modulates the infant microbiome and intestinal Flt3L necessary for dendritic cell development and immunity to respiratory infection
.
Immunity
.
56
:
1098
1114.e10
.
106.
Le Voyer
,
T.
,
A.V.
Parent
,
X.
Liu
,
A.
Cederholm
,
A.
Gervais
,
J.
Rosain
,
T.
Nguyen
,
M.
Perez Lorenzo
,
E.
Rackaityte
,
D.
Rinchai
, et al
.
2023
.
Autoantibodies against type I IFNs in humans with alternative NF-κB pathway deficiency
.
Nature
.
623
:
803
813
.
107.
Beck
,
D.B.
,
M.A.
Ferrada
,
K.A.
Sikora
,
A.K.
Ombrello
,
J.C.
Collins
,
W.
Pei
,
N.
Balanda
,
D.L.
Ross
,
D.
Ospina Cardona
,
Z.
Wu
, et al
.
2020
.
Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease
.
N. Engl. J. Med.
383
:
2628
2638
.
108.
Lin
,
Y.
,
C.
Zeng
,
X.
Chen
,
T.
Li
,
H.
Liu
,
H.
Liu
,
H.
Hu
, and
L.
Liu
.
2020
.
Chinese family with Blau syndrome: Mutated NOD2 allele transmitted from the father with de novo somatic and germ line mosaicism
.
J. Dermatol.
47
:e395.
109.
Assrawi
,
E.
,
C.
Louvrier
,
E.
El Khouri
,
J.
Delaleu
,
B.
Copin
,
F.
Dastot-Le Moal
,
W.
Piterboth
,
M.
Legendre
,
S.A.
Karabina
,
G.
Grateau
, et al
.
2022
.
Mosaic variants in TNFRSF1A: An emerging cause of tumour necrosis factor receptor-associated periodic syndrome
.
Rheumatology (Oxford)
.
62
:
473
479
.
110.
Kontzias
,
A.
,
S.K.
Zarabi
,
C.
Calabrese
,
Y.
Wang
,
L.
Judis
,
Q.
Yao
, and
Y.W.
Cheng
.
2019
.
Somatic mosaicism in adult-onset TNF receptor-associated periodic syndrome (TRAPS)
.
Mol. Genet. Genomic Med.
7
:e791.
111.
Ionescu
,
D.
,
A.
Peñín-Franch
,
A.
Mensa-Vilaró
,
P.
Castillo
,
L.
Hurtado-Navarro
,
C.
Molina-López
,
S.
Romero-Chala
,
S.
Plaza
,
V.
Fabregat
,
S.
Buján
, et al
.
2022
.
First description of late-onset autoinflammatory disease due to somatic NLRC4 mosaicism
.
Arthritis Rheumatol.
74
:
692
699
.
112.
Terré
,
A.
,
F.
Magnotti
,
J.M.
Piot
,
G.
Boursier
, and
S.
Georgin-Lavialle
.
2024
.
Pyrin-associated autoinflammatory disease with p.Thr577Ala MEFV somatic mutation
.
Eur. J. Intern. Med.
120
:
139
141
.
113.
Parentelli
A.S.
,
G.
Boursier
,
L.
Cuisset
, and
S.
Georgin-Lavialle
.
2024
.
[Genetic mosaicism in systemic auto-inflammatory diseases: A review of the literature]
.
Rev. Med. Interne.
45
:
696
702
.
114.
Willemsen
,
M.
,
W.
Roosens
,
F.
Staels
,
T.H.M.
Schoonbrood
, and
R.
Schrijvers
.
2024
.
NLRC4-associated autoinflammatory disease: Insights from mouse models and somatic variants
.
J. Allergy Clin. Immunol.
155
:
803
807
.
115.
Van Horebeek
,
L.
,
B.
Dubois
, and
A.
Goris
.
2019
.
Somatic variants: New kids on the block in human immunogenetics
.
Trends Genet.
35
:
935
947
.
116.
Conrad
,
N.
,
S.
Misra
,
J.Y.
Verbakel
,
G.
Verbeke
,
G.
Molenberghs
,
P.N.
Taylor
,
J.
Mason
,
N.
Sattar
,
J.J.V.
McMurray
,
I.B.
McInnes
, et al
.
2023
.
Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: A population-based cohort study of 22 million individuals in the UK
.
Lancet
.
401
:
1878
1890
.
117.
Brown
,
G.J.
,
P.F.
Cañete
,
H.
Wang
,
A.
Medhavy
,
J.
Bones
,
J.A.
Roco
,
Y.
He
,
Y.
Qin
,
J.
Cappello
,
J.I.
Ellyard
, et al
.
2022
.
TLR7 gain-of-function genetic variation causes human lupus
.
Nature
.
605
:
349
356
.
118.
Nikolic
,
R.P.A.
, and
C.
Moran Toro
.
2023
.
Childhood-onset COPA syndrome recognized retrospectively in the context of polyarticular juvenile idiopathic arthritis and rheumatoid arthritis
.
Case Rep. Rheumatol.
2023
:
3240245
.
119.
Brehm
,
A.
,
Y.
Liu
,
A.
Sheikh
,
B.
Marrero
,
E.
Omoyinmi
,
Q.
Zhou
,
G.
Montealegre
,
A.
Biancotto
,
A.
Reinhardt
,
A.
Almeida de Jesus
, et al
.
2015
.
Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production
.
J. Clin. Invest.
125
:
4196
4211
.
120.
Kanazawa
,
N.
,
H.
Hemmi
,
N.
Kinjo
,
H.
Ohnishi
,
J.
Hamazaki
,
H.
Mishima
,
A.
Kinoshita
,
T.
Mizushima
,
S.
Hamada
,
K.
Hamada
, et al
.
2021
.
Heterozygous missense variant of the proteasome subunit β-type 9 causes neonatal-onset autoinflammation and immunodeficiency
.
Nat. Commun.
12
:
6819
.
121.
Niihori
,
T.
,
M.
Ouchi-Uchiyama
,
Y.
Sasahara
,
T.
Kaneko
,
Y.
Hashii
,
M.
Irie
,
A.
Sato
,
Y.
Saito-Nanjo
,
R.
Funayama
,
T.
Nagashima
, et al
.
2015
.
Mutations in MECOM, encoding oncoprotein EVI1, cause radioulnar synostosis with amegakaryocytic thrombocytopenia
.
Am. J. Hum. Genet.
97
:
848
854
.
122.
Germeshausen
,
M.
,
P.
Ancliff
,
J.
Estrada
,
M.
Metzler
,
E.
Ponstingl
,
H.
Rütschle
,
D.
Schwabe
,
R.H.
Scott
,
S.
Unal
,
A.
Wawer
, et al
.
2018
.
MECOM-Associated syndrome: A heterogeneous inherited bone marrow failure syndrome with amegakaryocytic thrombocytopenia
.
Blood Adv.
2
:
586
596
.
123.
Bastard
,
P.
,
S.E.
Vazquez
,
J.
Liu
,
M.T.
Laurie
,
C.Y.
Wang
,
A.
Gervais
,
T.
Le Voyer
,
L.
Bizien
,
C.
Zamecnik
,
Q.
Philippot
, et al
.
2023
.
Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs
.
Sci. Immunol.
8
:eabp8966.
124.
Lin
,
S.C.
,
F.R.
Zhao
,
H.
Janova
,
A.
Gervais
,
S.
Rucknagel
,
K.O.
Murray
,
J.L.
Casanova
, and
M.S.
Diamond
.
2023
.
Blockade of interferon signaling decreases gut barrier integrity and promotes severe West Nile virus disease
.
Nat. Commun.
14
:
5973
.
125.
Cheng
,
A.
,
A.
Kashyap
,
H.
Salvator
,
L.B.
Rosen
,
D.
Colby
,
F.
Ardeshir-Larijani
,
P.J.
Loehrer
,
L.
Ding
,
S.O.
Lugo Reyes
,
S.
Riminton
, et al
.
2024
.
Anti-Interleukin-23 autoantibodies in adult-onset immunodeficiency
.
N. Engl. J. Med.
390
:
1105
1117
.
126.
Casanova
,
J.-L.
2025
.
Human immunity
.
J. Hum. Immun
.
1
:
e20250001
.

Author notes

*

I. Meyts and S.G. Tangye contributed equally to this paper.

Disclosures: I. Aksentijevich reported “other” from In Vitro Diagnostic Solutions during the conduct of the study. T. Morio reported personal fees from Takeda Pharmaceutical, CSL Behring, Japan Blood Product Organization, Asteras, Sanofi, Ono Pharma, and Amgen outside the submitted work. K.E. Sullivan reported personal fees from Immune Deficiency Foundation during the conduct of the study. T.R. Torgerson reported personal fees from Pharming healthcare and Takeda, and “other” from Eli Lilly outside the submitted work. I. Meyts reported grants from CSL Behring, Takeda, and Octapharma, and “other” from Boehringer-Ingelheim outside the submitted work. No other disclosures were reported.

This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by-nd/4.0/).